Novo Nordisk Debt to Equity Ratio 2006-2018 | NVO

Current and historical debt to equity ratio values for Novo Nordisk (NVO) over the last 10 years.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $92.237B $16.962B
Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural resources.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $334.531B 16.56
Pfizer (PFE) United States $222.518B 13.69
Novartis AG (NVS) Switzerland $182.129B 15.78
Merck (MRK) United States $168.755B 15.08
AbbVie (ABBV) United States $152.737B 15.57
Sanofi (SNY) France $104.713B 13.25
GlaxoSmithKline (GSK) United Kingdom $102.153B 13.97
Eli Lilly (LLY) United States $96.679B 19.20
AstraZeneca (AZN) United Kingdom $92.856B 9.72
Bristol-Myers Squibb (BMY) United States $92.237B 18.15